SHP656, a polysialylated recombinant factor VIII (PSA‐rFVIII): First‐in‐human study evaluating safety, tolerability and pharmacokinetics in patients with severe haemophilia A

INTRODUCTION: SHP656 is the first factor VIII (FVIII) product developed using polysialylation (PSA) technology, in which full‐length recombinant (r) FVIII (anti‐haemophilic factor [recombinant]) is conjugated with a 20 kDa PSA polymer. AIM: To compare the safety, immunogenicity and pharmacokinetics...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Haemophilia
Main Authors: Tiede, Andreas, Allen, Geoffrey, Bauer, Alexander, Chowdary, Pratima, Collins, Peter, Goldstein, Brahm, Jiang, Hongyu Jeanne, Kӧck, Kathleen, Takács, István, Timofeeva, Margarita, Wolfsegger, Martin, Srivastava, Shouryadeep
Format: Artigo
Sprog:Inglês
Udgivet: John Wiley and Sons Inc. 2019
Fag:
Original Articles
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7027936/
https://ncbi.nlm.nih.gov/pubmed/31778283
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/hae.13878
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker